New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
08:32 EDTSQNMSequenom price target raised to $5 from $4 at Wedbush
Wedbush raised its price target on Sequenom after Quest agreed to begin using the company's MaterniT21 Plus test for fetal chromosomal abnormalities. The firm notes that the deal displaces one of Sequenom's competitors, and says that it will allow Sequenom to regain clear U.S. leadership of the category while improving its path to profitability. The firm keeps an Outperform rating on Sequnom.
News For SQNM From The Last 14 Days
Check below for free stories on SQNM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
14:41 EDTSQNMFDA draft lab tests guidelines not as bad as feared, says Piper Jaffray
Subscribe for More Information
July 30, 2014
08:39 EDTSQNMSequenom should be bought following solid Q2, says Maxim
Subscribe for More Information
July 29, 2014
18:35 EDTSQNMOn The Fly: After Hours Movers
Subscribe for More Information
16:33 EDTSQNMSequenom reports Q2 adjusted EPS (7c), consensus (11c)
Subscribe for More Information
16:32 EDTSQNMSequenom enters license agreement with Mayo Medical Laboratories
Subscribe for More Information
July 21, 2014
11:21 EDTSQNMSequenom VisibiliT launch unlikely to have near-term impact, says Ladenburg
Subscribe for More Information
07:02 EDTSQNMSequenom subsidiary launched VisibiliT test in international markets
Sequenom announced that its wholly owned subsidiary, Sequenom Laboratories, will soon launch the VisibiliT laboratory-developed test in international markets. The VisibiliT test utilizes maternal age, fetal fraction and the relative amount of chromosomal material for chromosomes 21 and 18 to generate a highly accurate, personalized risk score.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use